7210 Wareham Drive, Tampa, FL 33647
March 17, 2026 Weight Watchers reports its 2025 results yesterday. The firm’s revenues came in at $710 million, a 9.6% decline from 2024 revenues of $786 million. The company is expecting an 11% decrease in 2026 revenues, to between $620 and $635 million. 2025 Total Revenue and Adjusted EBITDA above high end of previously provided […]
Weight Watchers Reports Q4 & Full Year 2025 Results, 2026 Guidance Read More »
Feb. 18, 2026 Medifast reported full-year and Q4 2025 results on February 17, 2026. 2025 revenues came in at $386 million – a 36% decrease from $602 million in 2024. The company employed 16,100 active earning Optavia health coaches, who had quarterly earnings of $4,664 (or $18,656 on an annual rate). “As we enter 2026,
Medifast Reports Q4 and Full Year 2025 Results Read More »
Jan. 6, 2026 Novo Nordisk launched the pill version of its popular obesity medication Wegovy on Monday Jan. 5. The firm aimed to capture patients with a cash-pay discount — $149 a month for the lowest starting doses of the medication through April 15. It’s also trying to onboard new patients through a growing number
Telehealth Companies Offer Novo’s Wegovy pill Read More »
Nov. 17, 2025 Due to increased competition in the weight loss market and intense pressure from President Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and diabetes drugs for cash-paying patients. This is is the latest step in the firm’s efforts to provide discounts to Americans willing to buy
Novo Nordisk Lowers Weight Loss Drug Prices Read More »
Nov. 6, 2025 CNBC reported today that President Donald Trump announced deals with Eli Lilly and Novo Nordisk and Eli Lilly toslash the prices of some of their obesity drugs, including upcoming pills, in a landmark effort to expand access to the costly blockbuster treatment. The agreements will cut prices of so-called GLP-1 drugs for
Trump Cuts Deal To Lower Weight Loss Drug Prices Read More »
Nov. 6, 2025 According to WW management: “WeightWatchers is entering a new era, uniquely positioned at the intersection of medical innovation and behavioral science, to lead this rapidly evolving weight health market,” said Tara Comonte, CEO of WeightWatchers. “GLP-1s are a breakthrough in obesity care, but real success, with or without medication, comes from combining
Weight Watchers Reports 3rd Qtr. Results Read More »
Nov. 4, 2025 Management reported the foillowing: Revenue: $89.4 million, with revenue per active earning coach of $4,585 Active Coaches: Independent active earning OPTA VIA ® coaches of 19,500 Net Loss: $2.3 million or $0.21 loss per diluted share Strong Balance Sheet: $173.5 million in cash, cash equivalents, and investment securities with no debt “We’re transforming Medifast from a
Medifast Reports Q3 Results – Slide Continues Read More »
Sept. 23, 2025 Soon, there may be a promising alternative for the needle-averse, as results of a recent Phase 3 trial confirmed that a daily 25-milligram semaglutide pill can trigger significant weight loss. “We all knew this was coming, and we all feel that it could potentially be a game changer in terms of adopting
Weight Loss Pills Are On The Horizon Read More »
Sept. 23, 2025 Pfizer has agreed to pay up to $7.3 billion for weight-loss drug developer Metsera in a deal that provides a re-entry for the company into the market for obesity drugs. Pfizer on Monday said it will pay an initial $47.50 a share, or about $4.9 billion, for Metsera, a nearly 43% premium
Pfizer to Buy Weight-Loss Drug Developer Metsera Read More »
Sept. 3, 2025 WW announced the appointment of Alejandro Bethlen as Executive Vice President, International, effective immediately. In this role, Bethlen will oversee WeightWatchers’ business outside of the United States, driving international growth and innovation across the Company’s global footprint. “Alejandro’s international experience and commercial leadership make him uniquely suited to advance our growth outside
Weight Watchers Hires New International V.P. Read More »